Methods Women attending health services across Australia provided a self-collected (vaginal) or clinician-collected (cervical) specimen for HPV genotyping (Roche Linear Array) and completed a questionnaire. HPV vaccination status was validated against the National HPV Vaccination Program Register. Odds ratios (ORs) and 95% confidence intervals (CI) were calculated for factors associated with detection of any oncogenic HPV (HPV16/18/31/33/35/39/45/51/52/56/58/59/66/68).

Results Among 1,643 women, vaccine coverage ($\geq$ one dose) was 61.5% (69.1%, 58.7% and 41.1% among those 18–24, 25–29 and 30+ years, respectively). Oncogenic HPV prevalence was 25.4% (95% CI: 23.2–27.6%). In univariable analysis, risk factors for detection included younger age (p -trend <0.001), being a current smoker ($p=0.05$), and reporting more lifetime (p -trend <0.001) and recent (last 12 months) sexual partners (p -trend <0.001). In multivariable analysis, younger age (adjusted OR=1.33 [1.17–1.52]), more lifetime (adjusted OR=1.33 [1.16–1.52]) and recent sexual partners (adjusted OR=2.37 [1.77–3.16]) remained significant. There were no associations with socioeconomic status, area of residence or vaccination history. HPV16/18 prevalence was 1.4% (0.9–2.1%). In univariable analysis, risk factors for detection included older age ($p=0.05$), being non-Australian born ($p=0.05$), and being unvaccinated ($p<0.001$). In multivariable analysis, being unvaccinated remained the only factor significantly associated with HPV16/18 detection (adjusted OR=8.61 [2.45–30.25]). There were no associations with area of residence, socioeconomic status, or sexual behaviour.

Conclusion Oncogenic HPV was commonly detected among young Australian women; prevalence was influenced by risk factors related to sexual behaviour. In contrast, prevalence of quadrivalent vaccine-targeted types 16/18 was very low and influenced only by vaccination status. Vaccination has changed the epidemiology of HPV infection in Australia.

Disclosure No significant relationships.

P823

COMPARISON OF COPAN URISPONGE™ TO COLLI-PEE FOR THE COLLECTION OF URINE FOR HPV DETECTION WITH MOLECULAR ASSAYS

¹Santina Castriciano*, ²Marianna Martinelli. ¹Copan Italia Spa, Scientific Affairs, Hamilton, Canada; ²Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

10.1136/sextrans-2019-sti.868

Background Urine specimen collection is non-invasive and better accepted by patients for HPV and STI screening. The Copan UriSponge™, a Liquid Based Microbiology device, used for urine collection for culture and molecular assays. It consists of a leak-proof tube with a screw cap containing a plastic stick with sponges attached that absorb and retain the urine sample during transport preventing bacterial overgrowth. The objective of this study was to compare the UriSponge™ (US) to the Colli-Pee (CP) (Novosanis) urine devices for self-collection of first void urine (FVU) for the detection of HPV with the Seegene AnyplexII™-HPV28-assay.

Methods FVU, from 72 patients with a recent diagnosis of cervical dysplasia, attending the Gynecology clinic for colposcopy. 20 ml of first-void urine were collected using Colli-Pee™ and an additional aliquot of urine was collected in sterile containers to saturate UriSponge™. Nucleic acids were extracted by NucliSENS easyMAG (bioMérieux) from US and CP urine. HPV detection was performed using AnyplexII™

HPV28-Assay. Sample cellularity was evaluated with a quantitative real-time PCR detecting human CCR5 gene.

Results Out of 72 urines tested 24 (33.3%) were positive for HR-HPV, 16 (22.2%) for HR+LR, 8 (11.1%) for LR and 24 (22.2%) were negative from both US and CP. Comparable cellularity was present in US and CP with a mean value of 2.09×10^6 . Optimal concordance for all HR- HPV genotypes compared to cervical sample was demonstrated for US and CP. HPV 16, 18, 51 and 31 were most frequently HR-HPV genotypes.

Conclusion Data obtained in this study demonstrated that the Copan UriSponge™ detected all HR-HPV positive samples and good cellularity compared to the cervical swab when compared to the Novosanis Colli-Pee™ using the Seegene Anyplex™ II HPV28 assay. The UriSponge™ is easy to use for urine self-collection, it's not bulky, can be conveniently shipped by mail at a relatively low cost.

Disclosure No significant relationships.

P824

ACCURACY OF CERVICAL CANCER SCREENING USING A SELF-COLLECTED VIAL FOR HPV DNA TESTING AMONG ADULT WOMEN IN SUB-SAHARAN AFRICA

¹Zita Aleyo Ndjikoumbaye, ¹Damtheou Sadjoli, ²Ralph Sydney Mboumba Bouassa*, ³Hélène Péré, ³David Veyer, ⁴Chatté Adawaye, ³Mathieu Matta, ³Leman Robin, ⁵Serge Tonen-Wolyec, ⁶Moll Mahamat Tcheguena, ⁷Ali Mahamat Moussa, ⁸Donato Koyalta, ³Laurent Bélec. ¹Service de Gynécologie-Obstétrique, Hôpital de la Mère et de l'Enfant, and Cabinet Médical de Gynécologie Obstétrique 'La Renaissance Plus', N'Djamena, Chad; ²Ecole Doctorale Régionale d'Infectiologie Tropicale de Franceville, Franceville, Gabon; ³Laboratoire de Virologie, Hôpital Européen Georges Pompidou and Faculté de Médecine Paris Descartes, Université Paris Descartes (Paris V), Sorbonne Paris Cité, Paris, France; ⁴Institut National Supérieur des Sciences et Techniques d'Abéché, N'Djamena, Chad; ⁵Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Republic of Congo; ⁶Faculté de Médecine, N'Djamena, Chad; ⁷Service de Gastro-entérologie, Hôpital Général de Référence Nationale, N'Djamena, Chad; ⁸UNAIDS, N'Djamena, Chad

10.1136/sextrans-2019-sti.869

Background Cervical cancer is caused by HR-HPV infection. Self-collection of genital specimens and HPV DNA testing are methods increasing screening rates. The GYNAUTO-CHAD study compared the acceptability and HPV DNA diagnostic accuracy of clinician-collected endocervical sample with swab (as reference collection) and genital self-collection method with veil (V-Veil-Up Gyn Collection Device, V-Veil-Up Pharma Ltd., Nicosia, Cyprus) in adult women living in N'Djamena, Chad.

Methods Five of the 10 districts of N'Djamena were randomly selected for inclusion. Peer educators contacted women to participate to the survey by coming to the clinic for women's sexual health 'La Renaissance Plus'. A clinician performed pelvic examination and endocervical sampling using swab. Genital secretions were also obtained by self-collection using veil. Both clinician- and self-collected specimens were tested for HR-HPV DNA using Anyplex™ II HPV28 genotyping test (Seegene, Seoul, South Korea). Acceptability and accuracy of both collection methods were assessed.

Results 253 women (mean, 35.0 years) were prospectively enrolled. HPV prevalence was 22.9%, including 68.9% of HR-HPV (total HR-HPV prevalence: 15.8%), with unusual HR-HPV genotypes distribution and preponderance (70%) of HR-HPV targeted by Gardasil-9® vaccine. Veil-based genital self-collection showed high acceptability (96%), feasibility and satisfaction. Self-collection by veil was non-inferior to